

The effects of hypertension as an existing comorbidity on mortality rate in patients with COVID-19

A systematic review and meta-analysis.

Warwick Medical School, University of Warwick, Medical School Building, Coventry, CV4 7HL

Elena Whiteman BSc MSc

Medical Student

Correspondence to [elena.whiteman@warwick.ac.uk](mailto:elena.whiteman@warwick.ac.uk)

Word Count 2942 (excluding abstract, tables, figures, references, acknowledgments and supplementary material)

## Summary

Risk of mortality is considerably higher in hospitalised COVID-19 patients who have hypertension as an existing comorbidity prior to admission.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## Abstract

**Introduction:** Coronavirus has spread throughout the world rapidly, and there is a growing need to identify host risk factors to identify those most at risk. There is a growing body of evidence suggesting a close link exists between an increased risk of infection and an increased severity of lung injury and mortality, in patients infected with COVID-19 who have existing hypertension. This is thought to be due to the possible involvement of the virus target receptor, ACE2, in the renin-angiotensin-aldosterone blood pressure management system.

**Objective:** To investigate the association between hypertension as an existing comorbidity and mortality in hospitalized patients with confirmed coronavirus disease 2019 (COVID-19).

**Methods:** A systematic literature search in several databases was performed to identify studies that comment on hypertension as an existing comorbidity, and its effect on mortality in hospitalized patients with confirmed COVID-19 infection. The results of these studies were then pooled, and a meta-analysis was performed to assess the overall effect of hypertension as an existing comorbidity on risk of mortality in hospitalized COVID-19 positive patients.

**Results:** A total of 12243 hospitalised patients were pooled from 19 studies. All studies demonstrated a higher fatality rate in hypertensive COVID-19 patients when compared to non-hypertensive patients. Meta-analysis of the pooled studies also demonstrated that hypertension was associated with increased mortality in hospitalized patients with confirmed COVID-19 infection (risk ratio (RR) 2.57 (95% confidence interval (CI) 2.10, 3.14),  $p < 0.001$ ;  $I^2 = 74.98\%$ ).

**Conclusion:** Hypertension is associated with 157% increased risk of mortality in hospitalized COVID-19 positive patients. These results have not been adjusted for age, and a meta-regression of covariates including age is required to make these findings more conclusive.

## **Introduction**

In early December 2019, the first cases of a pneumonia of unknown origin were reported in Wuhan, China. Whilst initially appearing to be a localised outbreak, centred around a seafood and wet animal wholesale market in Wuhan City, within weeks it had spread to over 200 different countries worldwide, and was declared a pandemic on 12th March [1]. As of the 19th June 2020, there were 8,577,196 coronavirus cases, and 456,269 reported deaths worldwide [2]. It has been established that the pathogen responsible for this disease is the SARS-CoV-2 virus [3], a member of the coronavirus family. The disease is now largely referred to as COVID-19. Whilst the origin of the virus remains to be identified, its symptoms have been well characterised, and these include; fever, cough, fatigue, sputum production, headache, haemoptysis, dyspnoea and lymphopenia [4]. The rapid spread of the virus and its high variability in symptoms and severity prompted rapid research into host risk factors. Several risk factors for poorer outcomes have been identified, including older age, male sex, existing comorbidities and obesity [5]. Of the existing comorbidities, hypertension and diabetes are most frequently present in COVID-19 sufferers [6]. The noticeable high prevalence of hypertension in COVID-19 infection, and the identification of the angiotensin-converting-enzyme 2 receptor (ACE2) as the viral target [7] has drawn significant interest to the involvement of hypertension in COVID-19 infection.

In the present study we conducted a systematic review with meta-analysis with an aim to summarise all available primary research which has examined whether hypertension is a risk factor for increased mortality in COVID-19 patients.

## **Methods**

### *Search strategy and Study Selection*

I performed a literature search of the studies published since the COVID-19 outbreak began (2019) until June 20, 2020, with no restrictions on country imposed. We ran our searches in Ovid-Embase, Ovid-Medline, and medRxiv using the following search terms: (exp hypertension/) OR (high blood pressure.mp. or hypertension) OR (hypertensive.mp.) AND the COVID-19 search strategy suggested by NICE, see Figure S1. The Web of Science database was also searched using the following terms: Topic= (COVID-19\* AND hypertension\*). If inclusion criteria was satisfied, the full-text of the articles was retrieved and reviewed in its entirety.

### *Inclusion and Exclusion Criteria and Data Collection*

The following inclusion criteria were considered when assessing the eligibility of the identified studies: empirical studies of hospitalised patients which include 10 or more participants that: 1) included patients with confirmed COVID-19 infection who also had arterial hypertension as an existing comorbidity prior to hospital admission at the time of COVID-19 diagnosis, 2) disclosed information on clinical outcomes defined as survival or in hospital mortality, and 3) compared clinical outcomes between hypertensive and non-hypertensive patients.

### *Assessment of Study Quality*

To assess quality of included studies in the meta-analysis, we used The Newcastle-Ottawa Scale for cohort studies (Figure S2), and the NIH quality assessment tool for case series studies (Figure S3).

### *Statistical Analysis*

We extracted the number of patients in each group (hypertensive vs non-hypertensive, died vs lived) and collated these in a table. We then calculated fatality rate (FR) as a percentage of patients that died out of the total number of patients within each group (hypertensive and non-hypertensive), and report these in our results section.

We used a random effect model to summarise our statistical synthesis and generate a forest plot; this model considers within subject variance, and between subject variance, which is likely to exist in our pooled sample. Risk ratio (RR), 95% confidence intervals (CI) and p-values for each study are reported, as well as an overall pooled effect size estimate.


Heterogeneity was assessed using the  $I^2$  statistic which estimates the percentage of variation in effect sizes that is due to heterogeneity between the studies; the higher the value of the  $I^2$  statistic [8], the more heterogeneity is present. For the purposes of this systematic review and meta-analysis, I will accept an  $I^2$  statistic of no more than 95%. We then performed a subgroup analysis according to study size, to determine if heterogeneity remained the same when smaller and larger studies were separated.

Statistical significance was assumed for  $p \leq 0.05$ . We used STATA (StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC) for all our calculations. RR is considered significant if 95% CI do not cross 1.

## Results

### Study selection

Using the described search strategy, we identified 92 studies suitable for full-text review. We excluded 73 studies because they did not meet the inclusion criteria, and included the remaining 19 studies [9–27] in the meta-analysis (Figure 1). The included 19 studies scored well on quality assessment (Table S1 & S2), and met our inclusion criteria.



**Figure 1.** Prisma flowchart outlining study selection.

### Study characteristics

The 19 studies included resulted in a pooled number of 12,243 patients with confirmed COVID-19 infection. Of these, data on hypertension as an existing comorbidity was available for 12,243 patients, and data on survival/mortality was available for 12,218 patients. We compared mortality rates in patients with hypertension ( $n = 3,566$ ) and patients

without ( $n = 8,677$ ). The study characteristics, including study design, hospital location, hospital admittance dates and final date of follow up can be seen in Table 1. Of the nineteen included studies, fourteen are from China, two are from Italy, two are from Iran, and one is from New York. Included studies are a mix of retrospective-cohort and retrospective case-series. All included studies define how COVID-19 was diagnosed, see Table 1, and clearly state the dates of admission for patients included in the studies; follow up period is not defined in all included studies, but ranged from 0 days to 4 weeks.

#### *Fatality rates in hypertensive vs non-hypertensive patients*

Comparing fatality rates in COVID-19 patients between those that are hypertensive ( $n = 3566$ ) and non-hypertensive ( $n = 8677$ ), there is a much higher fatality rate in the hypertensive group (30.5%) when compared to the non-hypertensive group (9.9%), see Table 2. Seven studies [10, 14, 16, 21, 24, 25, 26, 27] also report a statistically significant p-value of less than 0.01 when carrying out a between group comparison, i.e. when comparing mortality in the hypertensive vs non-hypertensive group; only two studies report an insignificant p-value of less than 0.05 [12, 15], see Table 2. It is important to note however, that only the study by Guan WJ et al was adjusted for age and smoking status; the remaining 18 studies were not adjusted for any covariates.

**Table 1.** Table of characteristics of included studies

First author	Location	Study design	Sample size	Hospital admittance dates	Sampling procedure	COVID 19 diagnosis method	Final date of follow up
Akbari A et al [9]	Fars, Iran	Retrospective case-series	440	18 February 2020 to 19 March 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	Not mentioned
Cao J et al [10]	Zhongnan Hospital, Wuhan, China	Retrospective case-series	102	3 January to 1 February 2020	All admissions	RT-PCR assay of pharyngeal swabs	15 February 2020
Chen T et al [11]	Tongji Hospital in Wuhan, China	Retrospective case-series	274	13 January to 12 February 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	28 February 2020
Fu L et al [12]	Union Hospital of Huazhong University of Science and Technology, Wuhan, China	Retrospective case-series	200	1 January to 30 January 2020	All admissions	RT-PCR assay of pharyngeal swabs	Not mentioned
Guan WJ et al [13]	575 hospitals across mainland China	Retrospective case-series	1590	11 December 2019 to 31 January 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	31 January 2020
Grasselli et al [14]	Lombardy ITU network (72 hospitals) Milan, Italy	Retrospective case-series	1035	20 February to 18 March 2020	Consecutive patients admitted to ITU	RT-PCR assay of nasal and pharyngeal swabs	25 March 2020
Li K et al [15]	Quarantine unit of Tongji Hospital, Wuhan, China	Retrospective case-series	102	31 January to 5 March 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	Not mentioned
Luo X et al [16]	Eastern Campus of Renmin Hospital, Wuhan University	Retrospective case-series	403	30 January to 25 February 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	25 February 2020

**Table 1.** (Continued)

Nikpouraghdam et al [17]	Baqiyatallah Hospital, Tehran, Iran	Retrospective case-series	2968	19 Feb to 15 April 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs or clinically diagnosed based on pathognomonic CT imaging features consistent with coronavirus pneumonia	Not mentioned
Richardson et al [18]	New York City (12 hospitals *)	Retrospective case-series	5700	1 March to 4 April 2020	Sequential patient admissions	RT-PCR assay of nasal and pharyngeal swabs	4 April 2020
Si S et al [19]	Renmin Hospital of Wuhan University, Wuhan, Hubei Province	Retrospective case-series	671	1 January to 23 February 2020	Consecutive patient admissions	RT-PCR assay of nasal and pharyngeal swabs	23 February 2020
Tedeschi et al [20]	10 hospitals across Italy	Retrospective cohort	609	22 February to 4 April 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	Not mentioned
Wang L et al [21]	Renmin Hospital of Wuhan University, Wuhan, China	Retrospective cohort	339	Jan 1 to Feb 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	4 weeks
Yan Y et al [22]	Tongji Hospital, Wuhan, China	Retrospective cohort	193	Jan 10 to Feb 24 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	Not mentioned
Yang G et al [23]	Hubei Provincial Hospital of Traditional Chinese Medicine, China	Retrospective cohort	251	January 5 to February 22 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	March 3 2020
Yao Q et al [24]	Dabieshan Medical Center, Huanggang city, Hubei Province, China	Retrospective cohort	108	January 30 to February 11 2020	Consecutive patient admissions	RT-PCR assay of nasal and pharyngeal swabs	March 3 2020



**Table 1.** (Continued)

Yuan M et al [25]	Central Hospital of Wuhan, China	Retrospective case-series	27	1 January to 25 January 2020	Consecutive patient admissions	RT-PCR assay of nasal and pharyngeal swabs	Not mentioned
Zhou F et al [26]	Jinyintan Hospital and Wuhan Pulmonary Hospital China	Retrospective cohort	191	Dec 29 2019 to Jan 31 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	Not mentioned
Zhou X et al [27]	Wuhan Fourth Hospital, Wuhan, Hubei Province, China	Retrospective case series	110	January 25 to February 20 2020	All admissions	RT-PCR assay of nasal and pharyngeal swabs	February 20 2020

\*North Shore University Hospital, Long Island Jewish Medical Center, Staten Island University Hospital, Lenox Hill Hospital, Southside Hospital, Huntington Hospital, Long Island Jewish Forest Hills, Long Island Jewish Valley Stream, Plainview Hospital, Cohen Children’s Medical Center, Glen Cove Hospital, Syosset Hospital

**Table 2.** Mortality and survival numbers in COVID-19 positive patients

First author	N	Patients with hypertension				Patients without hypertension				p-value	HR/Univariate OR (95%CI)
		n	Died	Lived	FR%	n	Died	Lived	FR%		
Akbari A et al	440	35	2	33	5.7	405	11	394	2.7		
Chen et al	274	93	54	39	58.1	181	59	122	32.6		
Cao J et al	102	28	11	17	39.3	74	6	68	8.1	<.001	
Fu L et al	200	101	22	79	21.8	99	12	87	12.1	.069	
Guan WJ et al	1590	269	28	241	10.4	1321	22	1299	1.7		1.58 (1.07-2.3) p-value= .002*
Grasselli et al	1035	509	195	314	38.3	526	114	412	21.7	<.001	
Li K et al	102	31	7	24	22.6	71	8	63	11.3	.138	2.30 (0.75-7.03) p-value= .120
Lou X et al	403	113	60	53	53.1	290	40	250	13.8	<.001	
Nikpouraghdam et al	2964	59	8	51	13.6	2905	231	2674	8.0		
Richardson et al	2634	1366	384	982	28.1	1268	169	1099	13.3		
Shi S et al	671	199	37	162	18.6	472	25	447	5.3		
Tedeschi et al	609	311	131	180	42.1	298	43	255	14.4		
Wang L et al	339	138	32	106	23.2	201	22	168	11.0	.031	
Yan Y et al	193	73	57	16	78.1	120	51	69	42.5		
Yang G et al	251	126	13	113	10.3	125	8	117	6.4		
Yao Q et al	108	16	7	9	43.8	92	3	89	3.3	.001	
Yuan M et al	27	5	5	0	100	22	5	17	22.7	.003	
Zhou F et al	191	58	26	32	44.8	133	28	105	21.1	.0008	3.05 (1.57 – 5.92) p-value= .0010
Zhou X et al	110	36	7	25	19.4	74	2	62	2.7	<.01	
Total	12243	3566	1086	2476	30.5	8677	859	7797	9.9		

\*adjusted for age and smoking status

FR= Fatality rate  
 HR= Hazard ratio  
 OR= Odds ratio




**Table 3.** Included studies reporting on age within hypertensive and non-hypertensive COVID-19 patients

First author	N	Patients with hypertension			Patients without hypertension			p-value
		Age (years)						
		n	Measurement type	Value	n	Measurement type	Value	
Guan WJ et al	1590	269	Mean (SD)	62.1 (12.5)	1321	Mean (SD)	46.2±15.6	
Grasselli et al	1035	509	Median (IQR)	66 (60-72)	526	Median (IQR)	62 (54-68)	
Tedeschi et al	609	311	Median (IQR)	76 (67-83)	298	Median (IQR)	57 (47-68)	<.001
Yang G et al	251	126	Median (IQR)	66 (61-73)	125	Median (IQR)	66 (57-76)	0.685
Zhou X et al	110	36	Mean (SD)	64.8(10.1)	74	Mean (SD)	54.3(14.8)	<.001
			Median average	69		Median average	62	
			Mean average	64		Mean average	50	
Total	3595	1251			2344			

**Table 4.** Included studies reporting on gender within hypertensive and non-hypertensive COVID-19 patients

First author	N	Patients with hypertension			Patients without hypertension			p-value
		Sex						
		n	Male (%)	Female (%)	n	Male (%)	Female (%)	
Guan WJ et al	1578	266	156 (58.7)	110 (41.3)	1312	748 (57.0)	564 (42.9)	
Tedeschi et al	609	311	225 (72.3)	86 (27.7)	298	185 (62.1)	113 (37.9)	
Yang G et al	251	126	62 (49.2)	64 (50.8)	125	61 (48.8)	64 (51.2)	0.952
Zhou X et al	110	36	19 (52.8)	17 (47.2)	74	41 (55.4)	33 (44.6)	0.795
Total	2548	739	462 (62.5)	277 (37.5)	1809	1035 (57.2)	774 (42.8)	



**Figure 2.** Hypertension and mortality in patients with COVID-19. Forest plot shows that hypertension was associated with increased mortality and sub-grouping larger and smaller studies demonstrates increased homogeneity in smaller studies

### *Overall estimation of effect size and subgrouping heterogeneity differences*

This meta-analysis uses a random effects model and demonstrates that the presence of hypertension as an existing comorbidity is associated with a 157% increased risk of mortality in patients diagnosed with COVID-19 (risk ratio (RR) 2.57 (95% confidence interval (CI) 2.10, 3.14),  $p < 0.001$ ;  $I^2 = 74.98\%$ ) (Figure 2). Fourteen of the nineteen included studies report a significant p-value of less than 0.05 and 95% confidence intervals that do not cross 1.

Overall heterogeneity in the random effects model was high ( $I^2 = 74.98\%$ ), suggesting that the effects of hypertension on mortality are not the same across all studies. Subgrouping studies according to size however, Figure 2, demonstrates that heterogeneity is highest in the larger studies ( $I^2 = 93.40\%$ ) and greater homogeneity is present in the smaller studies ( $I^2 = 58.87\%$ ). Of the four larger studies, only one crosses the line of no difference; this is in contrast to the smaller studies, of which four of fifteen cross the line of no difference.

### *Age and gender distributions within hypertensive patients*

Five studies [13, 14, 20, 23, 27] provided information on age within hypertensive and non-hypertensive COVID-19 patients; three reported a median value [14, 20, 23], and two reported a mean [13, 27], see Table 3. Information on age was available for 3595 patients. Average age of patients with hypertension ( $n=1251$ ) in the three studies reporting a median value was 69, and 62 in non-hypertensive patients ( $n=2344$ ) (Table 3). Average age of COVID-19 positive patients with hypertension the two studies reporting a mean value was 64, and 50 in the non-hypertensive patients (Table 3). Age is therefore higher within the hypertensive patients. Although, only the study by Guan WJ et al adjusted their results for age within hypertensive and non-hypertensive patients. This study reported a hazard ratio of 1.58 (95%CI = 1.07-2.3,  $p$ -value = 0.002) when comparing mortality in hypertensive vs non-hypertensive patients, when adjusted for age and smoking status.

Information on sex was available for 2548 patients from four studies [13, 20, 23, 27]. The male sex predominated in both the hypertensive and non-hypertensive patients, at 62.5% and 57.2% respectively. Between group analysis was however, only available for two studies [23, 27] and this demonstrated insignificant results for both studies, Table 4, suggesting the sex differences in hypertensive and non-hypertensive patients may not be significant.

## Discussion

### *Summary of main findings*

We present data that indicates a significant increase in mortality in COVID-19 patients with hypertension as an existing comorbidity; all the included studies demonstrate a higher fatality rate in the hypertensive group when compared to the non-hypertensive group, and almost all report a statistically significant between group comparison with a p-value of less than 0.05. The two studies that do not [12, 15] are both very small studies, with only 201 and 102 patients each respectively. Bias within the study, or errors in data collection could therefore easily explain the disparity in results. An overall effect estimation also demonstrates a very significant overall contribution of hypertension to increased mortality in COVID-19 patients, with only five of the total nineteen included studies crossing the line of no difference and suggesting an insignificant result. Only one of these studies [17] is within the larger studies group; the remaining four studies [9, 12, 15, 23] are all within the smaller studies group, suggesting that within study biases could be to blame for the difference in results. The smaller studies do however, demonstrate a much greater homogeneity in results when compared to larger studies, which demonstrate very high heterogeneity.

Those studies that do report on age and gender within COVID-19 patients indicate that hypertension is more commonly present in males, and in older populations. Hypertension is known to be more common in males, and the elderly, although sex differences in prevalence of hypertension are reported to diminish after the age of 60 [28]. It is already known that elderly patients infected with COVID-19 are at an increased risk for progression to a severer form of the disease, and at an increased risk of mortality when compared to younger individuals [29]. The results of this meta-analysis would suggest that the added effects of the presence of hypertension may increase this risk even further across all age groups, and this may be specifically relevant to the elderly, who are already at an increased risk. This meta-analysis however, was not adjusted for age as a co-variate and therefore the effects seen may be a mere reflection of the increased risk of mortality in hypertensive patients [30] that exists irrespective of COVID-19 infection; it would be necessary to perform a meta-regression to separate these variables and prove that the association seen is in fact true. Similarly, recent studies have identified that the male sex is more likely to die from COVID-19 infection [31]: the results of this systematic review identify that the percentage of males in both hypertensive and non-hypertensive groups, in included studies that do report on sex difference, demonstrate that males are higher in both groups. We have already mentioned that hypertension is known to be higher in males; the high prevalence of males in both the hypertensive and non-hypertensive COVID-19 patients however may suggest that these variables are indeed separate. Only four studies report on COVID-19 sex differences, and none report differences in mortality that are adjusted for

sex. Again, a meta-regression for sex as a co-variate would be necessary to determine if the effects of hypertension are still present in the absence of sex as a potential confounding variable.

### *The ACE2 receptor and hypertension in COVID-19*

Whilst the association between COVID-19 pathogenesis and hypertension remains to be fully investigated, the proposed mechanisms by which this virus is interlinked with hypertension could be closely linked to the target receptor for this virus, ACE2, and its involvement in the renin-angiotensin-aldosterone system (RAAS). Internalisation of the COVID-19-ACE2 receptor complex would theoretically result in reduced expression of ACE2 on cell surfaces. This could then impede the cells ability to degrade angiotensin II, a necessary step to ensure correct blood pressure homeostasis.

Furthermore, hypertension is a known risk factor for increased mortality [32], and is known to cause myocardial injury [39]. Interestingly, whilst death from acute respiratory distress syndrome (ARDS) predominates in COVID-19 cases [33], there have been an increasing number of reports on myocardial injury also causing many COVID-19 deaths [34]. This could be due to increased myocardial demand that normally accompanies a viral illness, although there are several reports that a failure to appropriately metabolise angiotensin II may compromise cardiac function [35, 36], and we have already mentioned that the loss of ACE2 could interfere with this process. It remains to be established then, whether the combined effects of existing hypertension increasing risk of myocardial injury, together with the possible malfunctioning of angiotensin II metabolism in COVID-19 infection, together are causing increased risk of myocardial injury, and therefore increased mortality in hypertensive patients. Indeed, if one were to look at the results of the study by Chen T et al, it is clear to see patients with a previous history of hypertension dominated in the group of patients that developed acute cardiac injury (61% of patients) [37], although the differences in those that ultimately died does not seem as significant (77% vs 76%); the association remains to be explored.

Another possible consideration could be the management that severe COVID-19 patients which likely have a poor prognosis require. Patients who develop hypoxemic respiratory failure in ARDS will usually require mechanical ventilation [38], a process which requires general anaesthesia and loss of autonomous airway management. Hypertension is a known risk factor for complications in the application of general anaesthetic, with patients at an increased risk of greater swings in blood pressure than the normal population, followed by increased cardiovascular morbidity [39]. The increased risk that hypertension confers on mortality in COVID-19 patients could therefore be



due to the requirements for mechanical ventilation that most patients suffering from a critical form of COVID-19 infection will require, irrespective of their hypertensive status.

Similarly, hyper-coagulability has been reported in COVID-19 patients, with one study noting the development of in-hospital deep vein thrombosis (DVT) in 23% of patients, despite anticoagulant prophylaxis [40]. This could possibly be explained by the long hospital-stays COVID-19 patients are faced with, although appropriate anticoagulant prophylaxis has been shown to reduce the chances of in-hospital DVTs down to 2% [41]. Hypertension is known to confer a hyper-coagulable state [42] through its well-known contributions to Virchow's triad. Several cases of pulmonary embolisms in COVID-19 patients, in some cases bilateral, have been reported [43, 44], and these embolisms have been identified as the cause of death in some of these patients [45]. Whether or not hypertension is present in these patients however, remains unreported. It could be postulated that hypertension may be causing endothelial wall damage, thus contributing to a hyper-coagulable state, contributing to pulmonary embolisms and thus increasing mortality in COVID-19 via this mechanism. Again, this link remains to be further explored.

#### *Limitations and strengths*

This meta-analysis does demonstrate a significantly increased risk of mortality in hypertensive COVID-19 patients admitted to hospital; however, only 12243 patients were included. To date, there have been 8,577,196 reported cases of COVID-19 worldwide and so this sample is not largely representative, and a much larger sample of patients would be needed to make these findings conclusive. The reason for such a small sample of inclusion, at least at present, is the lack of studies due to the novel nature of this disease; as time progresses, I expect there to be many more studies eligible for inclusion in a similar systematic review in future. A large level of heterogeneity between studies was also present, and this is likely to be due to confounding factors which were not controlled for in the studies. These factors can include smoking status, ethnicity, additional comorbidities, amongst others. There may also be significant discrepancies in how data was collected across all studies, as the studies included fail to define how 'existing hypertension' was classified. The follow-up period is also very limited, again owing to the novel nature of this disease, and therefore the mortality figures may be skewed; a longer follow up period would be preferred to allow a bigger catchment time to assess mortality in patients who were only recently admitted at the time of writing. Finally, COVID-19 is a worldwide pandemic but the included studies are not descriptive of all regions of the world. Notably, most of the included studies are from China, with only two from Italy, two from Iran, and one from New York.; it would be interesting to see the results of similar empirical studies from other affected areas in the world should they be published and translated in the near future. Finally, this meta-analysis did not adjust for covariates and so these results should

be interpreted with caution; a similar systematic review and meta-analysis, followed by a meta-regression is needed to make these results more conclusive.

## Conclusion

These findings demonstrate that hypertension is a significant risk factor for increased mortality in COVID-19 patients. However, the potential reasons for this are also discussed, and hopefully demonstrate that the relationship between hypertension and COVID-19 pathogenesis is unclear; how the renin-angiotensin-aldosterone-system comes into play with this, if it does, is also unclear. More studies from across the globe, which are well-controlled and consider essential co-variables, are needed to ensure these results can be generalized to all populations; a greater understanding of COVID-19 pathogenesis is also required to determine how hypertension is conferring an increased mortality in affected patients.

## Declaration of conflicting interests

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Patient and public involvement

The studies pooled in this meta-analysis all received ethical approval to waive the requirement for patient consent

## Funding

The author received no financial support for the research, authorship, and/or publication of this article.

## References

1. (2020), World Health Organisation, *WHO announces COVID-19 outbreak a pandemic*, (<http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>), accessed on 20<sup>th</sup> May 2020
2. (2020), Worldometer, COVID-19 Coronavirus Pandemic, <https://www.worldometers.info/coronavirus/>, accessed on 19<sup>th</sup> June 2020

3. Ahn DG, Shin HJ, Kim MH, et al. (2020), “Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)”, *Journal of Microbiology and Biotechnology*. **30**(3), 313–324.
4. Ren L.L, Wang YM, Wu ZQ, Xiang Z.C, Guo L, Xu T. (2020), “Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study”, *The Journal of Chinese Medicine*. **133**(9), 1015—1024
5. Docherty AB, Harrison EM, Green CA, Hardwick HE, et al. (2020), “Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study”, *British Medical Journal*. **369**
6. Atkins JL, Masoli J, Delgado J, Pilling LC, et al. (2020), “Preexisting comorbidities predicting severe COVID-19 in older adults in the UK biobank community cohort”, Preprint, *medrxiv*.
7. Hoffmann M, Kleine-Wever H, Kruger N, Muller M, Drotsten C, Phohlmann S. (2020), “The novel coronavirus 2019 (2019-nCoV) uses the SARS coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry in target cells”, *Cell*. **181**, 1–10
8. Jonathan J Deeks, Julian PT Higgins, Douglas G Altman. Chapter 10: Analysing data and undertaking meta-analyses, <https://training.cochrane.org/handbook/current/chapter-10#section-10-10>
9. Akbari A, Emami A, Javanmardi F, et al. (2020), “Early Epidemiological analysis of CoVID-19: first report from South of Iran”, *Research Square*. Preprint.
10. Cao J, Tu W-J, Cheng W, et al. (2020), “Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China”, *Clinical Infectious Diseases*. Preprint.
11. Chen T, Wu D, Chen H, et al. (2020), “Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.”, *BMJ* . **368**(1091)
12. Fu L, Fei J, Xiang H-X, et al. (2020), “Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study”, *medRxiv*. **86**
13. Guan W-jie, Liang W-hua, Zhao Y, et al. (2020, “Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis”, *European Respiratory Journal*. **55**(5)
14. Grasselli G, Zangrillo A, Zanella A, et al. (2020), “Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy”, *JAMA*. Preprint.
15. Li K, Chen D, Chen S, et al. (2020), “Radiographic findings and other predictors in adults with Covid-19”, *medRxiv*; Preprint.
16. Luo X, Xia H, Yang W, et al. (2020), “Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China”, *medRxiv*. Preprint.

17. Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, et al. (2020), “Epidemiological Characteristics of Coronavirus Disease 2019 (COVID-19) Patients in IRAN: A single Center Study”, *Journal of Clinical Virology*
18. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, et al. (2020), “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area”, *JAMA*. **323**(20), 2052—2059
19. Shi S, Qin M, Cai Y, Liu T, et al. (2020), “Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019”, *European Heart Journal*. **0**, 1–10
20. Tedeschi S, Giannella M, Bartoletti M, Trapani M, Tadolini M. (2020), “Clinical Impact of Renin- angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019”, *Clinical Infectious Disease*
21. L. Wang, W. He and X. Yu et al. (2020), “Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up”, *Journal of Infection*. **80**, 639—645
22. Yan Y, Yang Y, Wang F, et al. (2020), “Clinical characteristics and outcomes of patients with severe covid-19 with diabetes”. *BMJ Open Diabetes Research & Care*. **8**
23. Yang G, Tan Z, Zhou L, Yang M, et al. (2020), “Effects of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study”, *American Heart Association*
24. Yao Q, Wang P, Wang X, Qie G, et al. (2020), “Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients”, *Polish Archives of Internal Medicine*, preprint.
25. Yuan M, Yin W, Tao Z, et al. (2020), “Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China”, *PLoS One*. **15**, 1–10.
26. Zhou F, Yu T, Du R, Fan G, et al. (2020), “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”, *Lancet*. **395**, 1054–62
27. Zhou X, Zhu J, Xu T. (2020), “Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors”, *Clinical and experimental hypertension*. **42**(7), 656—660
28. Oglesby P, Ostfeld AM. (1965), “Epidemiology of hypertension”, *Progress in cardiovascular diseases*. **8**(2), 106—116
29. Jin JM, Bai P, He W, Wu F, et al. (2020), “Gender Differences in Patients With COVID-19: Focus on Severity and Mortality”, *Frontiers in Public Health*. **8**(152)
30. Simões E Silva AC, Teixeira MM. (2016), “ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis”, *Pharmacology Research*. **107**, 154—162

31. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, et al. (2020), “Acute Kidney Injury in Patients Hospitalized With COVID-19”, *Kidney International*. (20)
32. Wang D, Hu B, Hu C, et al. (2020), “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”, *JAMA*. **323** (11), 1061–1069
33. Zhou F, Yu T, Du R, et al. (2020), “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”, *Lancet*. **395**(10229), 1054—1062
34. Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM, Chappell MC. (2008), “Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart”, *Experimental Physiology*. **93**(5), 613—21
35. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K, Zhang C. (2014), “Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets”, *Nature Reviews Cardiology*. **11**(7), 413-26.
36. Patel VB, Zhong JC, Grant MB, Oudit GY. (2016), “Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure”, *Circulation Research*. **118**(8), 1313—26
37. Chen T, Wu D, Chen H, Yan W, et al. (2020), “Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study”, *BMJ*. 368
38. World Health Organization (2020), Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance, <https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>, accessed on 19<sup>th</sup> June 2020
39. Mayell A. Hypertension in anaesthesia. Anaesthesia UK, [https://www.wfsahq.org/components/com\\_virtual\\_library/media/1f063c489ff87dcb4dcccabd851f4b-596e20871496b83e6951765710db38b2-28-Hypertension-in-anaesthesia.pdf](https://www.wfsahq.org/components/com_virtual_library/media/1f063c489ff87dcb4dcccabd851f4b-596e20871496b83e6951765710db38b2-28-Hypertension-in-anaesthesia.pdf), accessed on 19<sup>th</sup> June 2020
40. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, et al. (2020), “COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure”, *Thrombosis and Haemostasis*. **120** (6), 998—1000
41. Amaragiri SV, Lees TA. (2000), “Elastic compression stockings for prevention of deep vein thrombosis”, *Cochrane database of systematic reviews*. (3)
42. Lip GY, Li-Saw-Hee FL. (1998), “Does hypertension confer a hypercoagulable state?”, *Journal of Hypertension*. **16**(7), 913—916
43. Gian Battista Danzi, Marco Loffi, Gianluca Galeazzi, Elisa Gherbesi. (2020), “Acute pulmonary embolism and COVID-19 pneumonia: a random association?”, *European Heart Journal*. **41** (19), 1858

44. Tveita A, Hestenes S, Sporastøyl ER, et al. (2020), “Pulmonary embolism in cases of COVID-19. Lungeembolisme ved covid-19”, *Tidsskr Nor Laegeforen.* **140**(8)
45. Wichmann D, Sperhake JP, Lütgehetmann M, et al. (2020), “Autopsy Findings and Venous Thromboembolism in Patients With COVID-19”, *Annals of Internal Medicine.* Preprint.

**Figure S1.** NICE recommended search strategy for COVID-19 OVID platform

1	exp coronavirus/
2	((corona* or corono*) adj1 (virus* or viral* or virinae*)).ti,ab,kw.
3	(coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan* or Hubei* or Huanan or "2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCov or "HCoV-19" or HCoV19 or CoV or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncover or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*).ti,ab,kw.
4	((((respiratory* adj2 (symptom* or disease* or illness* or condition*)) or "seafood market*" or "food market*") adj10 (Wuhan* or Hubei* or China* or Chinese* or Huanan*)).ti,ab,kw.
5	((outbreak* or wildlife* or pandemic* or epidemic*) adj1 (China* or Chinese* or Huanan*)).ti,ab,kw.
6	"severe acute respiratory syndrome".ti,ab,kw.
7	or/1-6
8	limit 7 to yr="2019 -Current"

**Figure S2.** Newcastle-Ottawa quality assessment form for cohort studies used to assess quality of included cohort studies

## Newcastle-Ottawa Quality Assessment Form for Cohort Studies

Note: A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

### Selection

- 1) Representativeness of the exposed cohort
  - a) Truly representative (*one star*)
  - b) Somewhat representative (*one star*)
  - c) Selected group
  - d) No description of the derivation of the cohort
- 2) Selection of the non-exposed cohort
  - a) Drawn from the same community as the exposed cohort (*one star*)
  - b) Drawn from a different source
  - c) No description of the derivation of the non exposed cohort
- 3) Ascertainment of exposure
  - a) Secure record (e.g., surgical record) (*one star*)
  - b) Structured interview (*one star*)
  - c) Written self report
  - d) No description
  - e) Other
- 4) Demonstration that outcome of interest was not present at start of study
  - a) Yes (*one star*)
  - b) No

### Comparability

- 1) Comparability of cohorts on the basis of the design or analysis controlled for confounders
  - a) The study controls for age, sex and marital status (*one star*)
  - b) Study controls for other factors (list) \_\_\_\_\_ (*one star*)
  - c) Cohorts are not comparable on the basis of the design or analysis controlled for confounders

### Outcome

- 1) Assessment of outcome
  - a) Independent blind assessment (*one star*)
  - b) Record linkage (*one star*)
  - c) Self report
  - d) No description
  - e) Other
- 2) Was follow-up long enough for outcomes to occur
  - a) Yes (*one star*)
  - b) No

Indicate the median duration of follow-up and a brief rationale for the assessment above: \_\_\_\_\_
- 3) Adequacy of follow-up of cohorts
  - a) Complete follow up- all subject accounted for (*one star*)
  - b) Subjects lost to follow up unlikely to introduce bias- number lost less than or equal to 20% or description of those lost suggested no different from those followed. (*one star*)
  - c) Follow up rate less than 80% and no description of those lost
  - d) No statement



**Figure S3.** National Heart, Lung, and Blood Institute Quality Assessment Tool for Case Series Studies used to assess quality of included case-series studies

Criteria	Yes	No	Other (CD, NR, NA)*
1. Was the study question or objective clearly stated?			
2. Was the study population clearly and fully described, including a case definition?			
3. Were the cases consecutive?			
4. Were the subjects comparable?			
5. Was the intervention clearly described?			
6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?			
7. Was the length of follow-up adequate?			
8. Were the statistical methods well-described?			
9. Were the results well-described?			
<b>Quality Rating (Good, Fair, or Poor)</b>			
Rater #1 initials:			
Rater #2 initials:			
Additional Comments (If POOR, please state why):			


\*CD, cannot determine; NA, not applicable; NR, not reported

**Table S1.** Newcastle Ottawa quality assessment for cohort studies


First Author, year	Selection (4)	Comparability (2)	Exposure/outcome (3)	Total score (9)
Tedeschi et al	***	*	***	7
Wang, L et al	**	*	**	5
Yan Y et al	***	*	**	6
Yang G et al	***	*	**	6
Yao Q et al	***	*	**	6
Zhou F et al	***	*	**	6

**Table S2.** NIH Quality Assessment Tool for Case Series Studies

First Author, year	Quality rating (good, fair, poor)
Akbari A et al	Good
Cao J et al	Good
Chen T et al	Good
Fu L et al	Good
Guan WJ et al	Good
Li K et al	Good
Luo X et al	Good
Grasselli et al	Good
Nikpourghadam et al	Good
Richardson et al	Good
Shi S et al	Good
Yuan M et al	Good
Zhou X et al	Good



**Figure 1.** Prisma flowchart outlining study selection.



**Figure 2.** Hypertension and mortality in patients with COVID-19. Forest plot shows that hypertension was associated with increased mortality and sub-grouping larger and smaller studies demonstrates increased homogeneity in smaller studies

**Figure S1.** NICE recommended search strategy for COVID-19 OVID platform

1	exp coronavirus/
2	((corona* or corono*) adj1 (virus* or viral* or virinae*)).ti,ab,kw.
3	(coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan* or Hubei* or Huanan or "2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCov or "HCoV-19" or HCoV19 or CoV or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncovor or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*).ti,ab,kw.
4	((((respiratory* adj2 (symptom* or disease* or illness* or condition*)) or "seafood market*" or "food market*") adj10 (Wuhan* or Hubei* or China* or Chinese* or Huanan*)).ti,ab,kw.
5	((outbreak* or wildlife* or pandemic* or epidemic*) adj1 (China* or Chinese* or Huanan*)).ti,ab,kw.
6	"severe acute respiratory syndrome".ti,ab,kw.
7	or/1-6
8	limit 7 to yr="2019 -Current"

**Figure S2.** Newcastle-Ottawa quality assessment form for cohort studies used to assess quality of included cohort studies

## Newcastle-Ottawa Quality Assessment Form for Cohort Studies

Note: A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

### Selection

- 1) Representativeness of the exposed cohort
  - a) Truly representative (*one star*)
  - b) Somewhat representative (*one star*)
  - c) Selected group
  - d) No description of the derivation of the cohort
- 2) Selection of the non-exposed cohort
  - a) Drawn from the same community as the exposed cohort (*one star*)
  - b) Drawn from a different source
  - c) No description of the derivation of the non exposed cohort
- 3) Ascertainment of exposure
  - a) Secure record (e.g., surgical record) (*one star*)
  - b) Structured interview (*one star*)
  - c) Written self report
  - d) No description
  - e) Other
- 4) Demonstration that outcome of interest was not present at start of study
  - a) Yes (*one star*)
  - b) No

### Comparability

- 1) Comparability of cohorts on the basis of the design or analysis controlled for confounders
  - a) The study controls for age, sex and marital status (*one star*)
  - b) Study controls for other factors (list) \_\_\_\_\_ (*one star*)
  - c) Cohorts are not comparable on the basis of the design or analysis controlled for confounders

### Outcome

- 1) Assessment of outcome
  - a) Independent blind assessment (*one star*)
  - b) Record linkage (*one star*)
  - c) Self report
  - d) No description
  - e) Other
- 2) Was follow-up long enough for outcomes to occur
  - a) Yes (*one star*)
  - b) No

Indicate the median duration of follow-up and a brief rationale for the assessment above: \_\_\_\_\_
- 3) Adequacy of follow-up of cohorts
  - a) Complete follow up- all subject accounted for (*one star*)
  - b) Subjects lost to follow up unlikely to introduce bias- number lost less than or equal to 20% or description of those lost suggested no different from those followed. (*one star*)
  - c) Follow up rate less than 80% and no description of those lost
  - d) No statement

**Figure S3.** National Heart, Lung, and Blood Institute Quality Assessment Tool for Case Series Studies used to assess quality of included case-series studies

Criteria	Yes	No	Other (CD, NR, NA)*
1. Was the study question or objective clearly stated?			
2. Was the study population clearly and fully described, including a case definition?			
3. Were the cases consecutive?			

4. Were the subjects comparable?			
5. Was the intervention clearly described?			
6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?			
7. Was the length of follow-up adequate?			

**Table S1.** Newcastle Ottawa quality assessment for cohort studies

First Author, year	Selection (4)	Comparability (2)	Exposure/outcome (3)	Total score (9)
8. Were the statistical methods well-described?				
9. Were the results well-described?				
Tedeschi et al	***	*	***	7
Wang L et al	**	*	**	5
Yan Y et al	***	*	**	6
Yang G et al	***	*	**	6
Yao Q et al	***	*	**	6
Zhou F et al	***	*	**	6



**Table S2.** NIH Quality Assessment Tool for Case Series Studies

First Author, year	Quality rating (good, fair, poor)
Akbari A et al	Good
Cao J et al	Good
Chen T et al	Good
Fu L et al	Good
Guan WJ et al	Good
Li K et al	Good
Luo X et al	Good
Grasselli et al	Good
Nikpourghadam et al	Good
Richardson et al	Good
Shi S et al	Good
Yuan M et al	Good
Zhou X et al	Good